Effect of co-occurring mutations in TP53 gene and TERT promoter on the survival of bladder cancer patients

Bladder urothelial cancer can be stratified into biologically and clinically distinct subtypes on the basis of cancer driver mutations, with concomitant <i>TERT</i>p/<i>TP53</i> nucleotide changes strongly linked to reduced patients' overall survival. These results suggest a potential cooperative interaction between mutant <i>TERT</i>p and <i>TP53</i> in the pathogenesis of bladder cancer, highlighting their significance as prognostic biomarkers and promising targets for novel therapeutic strategies.